Affiliation:
1. V.A. Nasonova Research Institute of Rheumatology
Abstract
Infection caused by hepatitis B virus (HBV) is one of the most common hemocontact infections. The special life cycle of the hepatitis B virus, the course of infection, often hidden, and the high risk of developing life-threatening conditions, such as fulminant hepatitis and hepatocellular carcinoma, make it necessary to exercise special caution when choosing therapeutic tactics for rheumatological patients, since the vast majority of drugs used in rheumatological practice have immunosuppressive properties. This review updates information on the risks of reactivation of HBV infection in the treatment of currently used antirheumatic drugs, considers difficult to curate variants of chronic hepatitis B with delta agent and extrahepatic manifestations, in particular, thrombocytopenia. The most systematic and consistent approach to ranking the risk of reactivation of HBV infection (low [less than 1 %], moderate [1–10 %] and high [higher than 10 %]), in accordance with the serological status of the patient, as well as the type and duration of immunosuppressive treatment used, is proposed by the American Gastroenterological Association. The authors have attempted to unify the current literature data according to this classification.
Subject
Materials Chemistry,Economics and Econometrics,Media Technology,Forestry
Reference88 articles.
1. Ivashkin VT, Yushchuk ND, Mayevskaya MV, et al. Clinical guidelines of the Russian gastroenterological association and the Russian society on studying of liver diseases on diagnostics and treatment of adult patients with hepatitis B. Russian Journal of Gastroenterology, Hepatology, Coloproctology, 2014; 24 (3): 58–88 (In Russ.).
2. Polaris Observatory Collaborators. Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: A modelling study. Lancet Gastroenterol Hepatol. 2018 Jun; 3 (6): 383–403. DOI: 10.1016/S 2468–1253(18)30056–6.
3. Hepatitis B. Fact sheet of WHO. 9 July 2021. Available at: https://www.who.int/ru/news-room/fact-sheets/detail/hepatitis-b
4. WHO Publication. Hepatitis B vaccines: WHO position paper – recommendations. Vaccine. 2010; 28 (3): 589–90. DOI: 10.1016/j.vaccine.2009.10.110.
5. Locarnini S. Molecular virology of hepatitis B virus. Semin Liver Dis. 2004; 24 Suppl 1: 3–10. DOI: 10.1055/s-2004–828672.
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献